Todd R. Golub - Nanotechnology

Author Information

Todd R. Golub is a prominent researcher affiliated with the Broad Institute of Harvard and MIT, located in Cambridge, MA, USA. His extensive research has significantly contributed to the fields of genomics and cancer biology, among others.

Research Contributions

Todd R. Golub has made substantial contributions to cancer research, particularly focusing on genomic evolution, cell death mechanisms, cancer vulnerabilities, and liquid biopsy techniques. His recent work includes investigating DNA-based copy number analysis, exploring the effects of copper on cell death, and identifying therapeutic vulnerabilities in ovarian cancer. His research also extends to understanding the clinical and genomic landscape of metastatic breast cancer through patient-partnered research.

Aliases

Todd R. Golub is also known by various aliases in academic publications, including Todd Golub, T R Golub, T. R. Golub, and T. Golub.

Publication and Citation Metrics

Metric	Count
Citation Count	197,854
h-index	168
Paper Count	543

Publications:

DNA-based copy number analysis confirms genomic evolution of PDX models

DOI: 10.1038/s41698-022-00268-6

Year: 2022

Copper induces cell death by targeting lipoylated TCA cycle proteins

DOI: 10.1126/science.abf0529

Year: 2022

Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal

DOI: 10.1101/2022.03.02.482624

Year: 2022

Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth.

DOI: 10.1038/s41551-022-00855-9

Year: 2022

Abstract OT1-19-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research

DOI: 10.1158/1538-7445.sabcs21-ot1-19-01

Year: 2022

Abstract PD6-02: The metastatic breast cancer project - Expanding the clinical, genomic, and transcriptomic landscape of metastatic breast cancer through patient-partnered research

DOI: 10.1158/1538-7445.sabcs21-pd6-02

Year: 2022

Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.

DOI: 10.1093/neuonc/noab299

Year: 2022

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.

DOI: 10.1038/s43018-022-00360-7

Year: 2022

FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS.

DOI: 10.1038/S43018-021-00183-Y

Year: 2021

Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q

DOI: 10.1016/j.celrep.2021.109367

Year: 2021

What are the Challenges in Integrating Nanotechnology with Wearables?

How Can Nanotechnology Aid in Neurological Rehabilitation?

What are the Key Features of Effective Endosome Disruptive Peptides?

What are the Limitations of EDS?

What are the Applications of Size-Reduced Nanomaterials?

What Are the Challenges in Using High Purity Precursors?

What are the Unique Properties of Nanorods?

How are High Throughput Experiments Conducted?

What is Lithium Iron Phosphate?

What are the Key Properties of Black Phosphorus?

Partnered Content Networks

Relevant Topics